REFERENCES

1. Extermann M. Measuring comorbidity in older cancer patients. Eur J Cancer, 36:453-71, 2000.
2. Mountain CF. Revisions in the international staging system for lung cancer. Chest, 111:1710-7, 1997.
3. Morandi U, Stefani A, Golinelli M, et al. Results of surgical resection in patients over the age of 70 years with non-small cell lung cancer. Eur J Cardiothorac Surg, 11:432-9, 1997.
4. Oliaro A, Leo F, Filosso PL, et al. Resection for bronchogenic carcinoma in the elderly. J Cardiovasc Surg 40:715-9, 1999.
5. de Perrot M, Licker M, Reymond MA, et al. Influence of age on operative mortality and long-term survival after lung resection for bronchogenic carcinoma. Eur Respir J, 14:419-22, 1999.
6. Ciriaco P, Zannini P, Carretta A, et al. Surgical treatment of non-small cell lung cancer in patients 70 years of age or older. Int Surg 83:4-7, 1998.
7. Yamamoto K, Padilla Alarcon J, et al. Surgical results of stage I non-small cell lung cancer: comparison between elderly and younger patients. Eur J Cardiothorac Surg 23:21-5, 2003.
8. Gauden SJ, Tripcony L. The curative treatment by radiation therapy alone of stage I non-small cell lung cancer in a geriatric population. Lung Cancer 32:71-9, 2001.
9. The International Adjuvant Lung Cancer Trial Collaborative Group. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small cell lung cancer. N Engl J Med 350:351-60, 2004.
10. Winton T, Livingston R, Johnson D, et al. Vinorelbine plus cisplatin vs. observation in resected non-small cell lung cancer. N Engl J Med 352:2589-97, 2005.
11. Strauss GM, Herndon J, Maddaus MA, et al. Randomized clinical trial of adjuvant chemotherapy with paclitaxel and carboplatin following resection in stage IB non-small cell lung cancer: report of Cancer and Leukemia Group B protocol 9633. J Clin Oncol, 22(14S):621s, 2004, Abstract #7019.
12. Douillard JY, Rosell R, Delena M, et al. ANITA: Phase III adjuvant vinorelbine and cisplatin versus observation in completely resected (stage I-III) non-small-cell lung cancer patients: final results after 70-month median follow-up. J Clin Oncol 23(16S): 624s, 2005, Abstract #7013.
13. Lonardi F, Coeli M, Pavanato G, et al. Radiotherapy for non-small cell lung cancer in patients aged 75 and over: safety, effectiveness and possible impact on survival. Lung Cancer 28:43-50, 2000.
14. Furuse K, Fukuoka M, Kawahara M, et al. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small cell lung cancer. J Clin Oncol 17:2692-9, 1999.
15. Curran WJ, Scott CB, Langer CJ, et al. Long-term benefit is observed in a phase III comparison of sequential vs. concurrent chemo-radiation for patients with unresected stage III NSCLC: RTOG 9410. Proc Am Soc Clin Oncol 22:621, 2003, Abstract #2499.
16. Lau DH, Crowley JJ, Gandara DR, et al. Southwest Oncology Group phase II trial of concurrent carboplatin, etoposide and radiation for poor-risk stage III non-small-cell lung cancer. J Clin Oncol 16:3078-81, 1998.
17. Langer CJ, Hsu C, Curran WJ, et al. Elderly patients with locally advanced non-small cell lung cancer benefit from combined modality therapy: secondary analysis of RTOG 94-10. Proc Am Soc Clin Oncol 21:299a, 2002, Abstract #1193.
18. Schild SE, Stella PJ, Geyer SM, et al. The outcome of combined-modality therapy for stage III non-small cell lung cancer in the elderly. J Clin Oncol 21:3201-6, 2003.
19. Fossella FV, Belani CP. Phase III study (TAX 326) of docetaxel-cisplatin and docetaxel-carboplatin versus vinorelbine-cisplatin for the first line treatment of advanced/metastatic non-small cell lung cancer: analyses in elderly patients. Proc Am Soc Clin Oncol, 22:629, 2003, Abstract #2528.
20. Lilenbaum RC, Herndon JE 2nd, List MA, et al. Single-agent versus combination chemotherapy in advanced non-small cell lung cancer: the Cancer and Leukemia Group B study 9730. J Clin Oncol 23:190-6, 2005.
21. The Elderly Lung Cancer Vinorelbine Italian Study Group. Effects of vinorelbine on quality of life and survival of elderly patients with advanced non-small cell lung cancer. J Natl Cancer Inst 91:66-72, 1999.
22. Gridelli C, Perrone H, Gallo C, et al. Chemotherapy for elderly patients with advanced non-small cell lung cancer: the Multicenter Italian Lung Cancer in the Elderly Study (MILES) phase III randomized. J Natl Cancer Inst 95:362-72, 2003.
23. Hainsworth JD, Burris HA, Litchy S, et al. Weekly docetaxel in the treatment of elderly patients with advanced non-small cell lung carcinoma. Cancer 89:328-33, 2000.
24. Shepherd FA, Abratt RP, Anderson H, et al. Gemcitabine in the treatment of elderly patients with advanced non-small cell lung cancer. Semin Oncol 24(suppl 7):50-5, 1997.
25. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al. Erlotinib in previously treated non-small cell lung cancer. N Engl J Med 353:123-32, 2005.
26. Tsao M-S, Sakurada A, Cutz J-C, et al. Erlotinib in lung cancer ?C molecular and clinical predictors of outcome. N Engl J Med 353:133-44, 2005.
27. Hensing TA, Socinski MA. Treatment of advanced non-small cell lung cancer in the elderly; the role of third-generation platinum-based combination chemotherapy. Am J Oncol Rev 3:146-54, 2004.
28. Hennessy BT, Hanrahan EO, Breathnach OS. Chemotherapy options for the elderly patient with advanced non-small cell lung cancer. Oncologist 8:270-7, 2003.
29. Lilenbaum R. Management of advanced non-small cell lung cancer in elderly populations. Clin Lung Cancer 5:169-73, 2003.
30. Makrantonakis PD, Galani E, Harper PG. Non-small cell lung cancer in the elderly. Oncologist 9:556-60, 2004.
31. Weinmann M, Jeremic B, Toomes H, et al. Treatment of lung cancer in the elderly. Part I: non-small cell lung cancer. Lung Cancer 39:233-53, 2002.